Home/Pipeline/SYNT-101

SYNT-101

Obesity

Phase 1/1bActive

Key Facts

Indication

Obesity

Phase

Phase 1/1b

Status

Active

Company

Syntis Bio

About Syntis Bio

Syntis Bio is a private, clinical-stage biotech founded in 2021 and based in Cambridge, Massachusetts. The company is pioneering a novel oral drug delivery platform, SYNT™, which uses a bio-inspired polymer to line the small intestine, thereby modulating nutrient absorption and enabling the oral delivery of peptides, enzymes, and other biologics. With a $38 million financing round closed in 2025, Syntis is advancing a pipeline led by SYNT-101 for obesity, which has entered Phase 1/1b trials. The company leverages world-class scientific founding from MIT and a leadership team with deep experience in bringing novel therapeutics and diagnostics to market.

View full company profile

Therapeutic Areas

Obesity Diabetes Rare Diseases

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active
VIAL-INHBE (siRNA)	VIAL Dermatology CRO	Phase 1	Active